Member Info for Wigwammer

So why are nolupus and halfbutt allowed to coexist? Same person. Bear it in mind people 🧐

Interesting you should say that xviolet. When asked about possible deal structures during the Q&A, Tim Franklin went through the standard format of upfront fee, milestones and royalties. But then he went on to describe something more unusual - an “optionality” type package - where a company pays an initial fee to develop the drug so far, with the option to take it further with additional payments at a later stage. GLA

Halfbutt and nolupus arrive within one minute of each other.. very curious indeed :)

Excellent post, crazyyear. All I would add is that the investment payoffs attached to each of the unknown outcomes is also assymetric. In simple terms, you cannot lose more than 100% owning IMM shares, but the potential upside is many multiples of 100% if the uncertainties are answered in our favour. The fully diluted market cap remains below £40m, while the potential is may multiples of this. IMO Not advice etc

Observation : msuk’s IMM calls are mixed at best, and he certainly hasn’t made the returns of some fundamental based investors here. But then stock returns are not really what motivates him. It’s more that - as a TA follower - he gets to preach, patronise and gloat on a regular basis (without turning much of a profit, or having qualifications in anything) … IMO DYOR GLA

You have already received an answer to that question, rog. 24/3/2026… You didn’t respond and it was a waste of my time. Now you want people to waste their time all over again..

With respect mysticmike, of course you have that right and you have expressed your view many times. But people here also have the right to point out that they have repeatedly tried to answer your points but that it doesn’t appear to make any difference to your thinking. If you can’t be convinced then it’s not clear what you want from this forum. IMO DYOR GLA

It has been discussed many times, roger, and you have been given answers. In addition, if avion have been waiting for patent fortification before proceeding, today’s RNS confirming the expedited route is good news, no? .. IMO DYOR GLA

I think it is more the endless repetition, roger and mysticmike. You repeat the same points every day and people have tried to answer you politely but it doesn’t make any difference. Are your posts trying to convince people here, or convince yourselves now you have sold your shares?

A large number of misleading and provocative posts have been removed this morning and over recent days. Thank you LSE

Interesting that they have confirmed use of the CSER route for the first time, which can knock 2-3 years off the patent application process. Things moving along nicely.. IMO DYOR GLA

Thanks juxta. With research like that I think everyone here will be happy making a market with you… GLA

The “everything is ok brigade” is precisely “ok” because they CAN separate the science from the leadership. If the science is compelling enough then a deal will happen, and holders will be rewarded. It is the “everything is Tim” brigade that are getting their knickers in a knot 24/7, precisely because they can’t make this separation.. IMO DYOR GLA

I agree it could take months, crazyyear, but we don’t know when IMM started the process to get publication. They lodged the patent application in early September last year - which gives them filing date protection - so it could have started any time after that… GLA IMO DYOR

With respect, mysticmike, I don’t think it does require a divorce from avion… immupharma will earn up to 17% royalties - that’s pure margin - on any sales made by avion of p140 into the US. Thats a pretty healthy royalty margin. How avion choose to manage their asset to get us there is really up to them, but it needn’t be a bind for us. There remains the question about how avion accesses the new patent discovery (pending!) but hopefully that too will move things a little more in our direction… IMO DYOR GLA

Immupharma is a tiny company, roger. 6 people. And the very point that multiple large pharma groups have shown interest in p140 is testament to the potential scale of asset this tiny company is trying to manage… So put yourself in their shoes. Multiple large companies are interested, and remain interested, and they grab your attention at the beginning. And then over the ensuing weeks/months smaller and mid sized groups engage more and more with you. They answer your calls, their scientists engage frequently with yours, they want to put your asset left/right/centre, and they have the money to make a competitive offer… And in the background the behemoths roll on - talking to their R&D dept about how p140 could fit in, and engaging with half a dozen other departments before returning your call... And suddenly the smaller companies look more exciting - they will treasure your asset and move with speed to do something with it… Suddenly pointing out that a potential partner is “big” no longer seems so interesting. But it doesn’t mean they aren’t still there. Just a thought… DYOR IMO GLA

Some good points, roby. Taking your 50/50 scenario though, bear in mind the payoff to each of those outcomes is probably not equal. You can’t lose more than 100% of your investment here, but you can make multiples of 100% if things go right… high risk, high reward and people should not invest more than they can afford to lose. But for me - the late stage of the drug , the multi billion usd end markets, low cash burn and small market cap make it attractive, along with the potential for brand new patent protection ! IMO DYOR GLA

At the same time, roger, there is no inference from Sebastien’s presentation that anybody has walked away. Listen again to Sebastien’s presentation and you will see what I mean … GLA

I think intelligent people get the picture about otm, without further prompting from me. GLA

Or they could announce something very soon, roger. There was no suggestion from Sebastien Goudreau CSO that any interested party has walked away, which means the pipeline of potential suitors is getting larger. IMO DYOR GLA